Errol de Souza
Chairman at CYCLERION THERAPEUTICS, INC.
Net worth: 31 M $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kevin Gorman | M | 66 | 32 years | |
| Srinivas Rao | M | 55 |
Kures, Inc.
 Kures, Inc. BiotechnologyHealth Technology Kures, Inc. engages in the development of therapeutics for mood disorders. The company is headquartered in Dobbs Ferry, NY. | 5 years |
| Rory Riggs | M | 71 | 28 years | |
| Peter Hecht | M | 60 | 5 years | |
| Terry McGuire | M | 68 | 11 years | |
| Gary Lyons | M | 73 | 31 years | |
| Brian McKeon | M | 61 | 21 years | |
| Arnon Rosenthal | M | 68 | 11 years | |
| Adrian Hinton | M | 72 | 5 years | |
| Andrés-Pablo Montefeltro | M | - |
nLife Therapeutics SL
 nLife Therapeutics SL Pharmaceuticals: MajorHealth Technology nLife Therapeutics SL develops and manufactures pharmaceutical preparations. It specializes in oligonucleotides as therapeutic agents for central nervous system and neuromuscular disorders. The company was founded by Andres Pablo Montefeltro on September 24, 2009 and is headquartered in Armilla, Spain. | 15 years |
| Pablo Legorreta | M | 60 | 28 years | |
| Alan Fisher | M | 71 | 8 years | |
| Danielle Pasqualone | M | - | 5 years | |
| Spyridon Papapetropoulos | M | 52 | 1 years | |
| Louis Lavigne | M | 75 | 6 years | |
| Peter Davies | M | 43 | 3 years | |
| Leslie Norwalk | F | 58 | 26 years | |
| George Lloyd | M | 64 | 13 years | |
| Saraswati Kenkare-Mitra | M | 56 | 3 years | |
| Bonnie Bassler | M | 61 | 4 years | |
| Catherine Engelbert | F | 59 | 4 years | |
| John Hart | M | - | 16 years | |
| George Grofik | M | - | 4 years | |
| Marc Grasso | M | 51 | 2 years | |
| Joseph Hull | M | 71 | 19 years | |
| Paula Hammond | M | 60 | 4 years | |
| Christopher Hite | M | 57 | 4 years | |
| Andrew Carry Kruegel | M | - |
Kures, Inc.
Kures, Inc. BiotechnologyHealth Technology Kures, Inc. engages in the development of therapeutics for mood disorders. The company is headquartered in Dobbs Ferry, NY. | - |
| Aaron Weaver | M | 43 | 4 years | |
| Elizabeth Garofalo | M | 66 | 3 years | |
| Kristine Yaffe | M | 61 | 5 years | |
| Mario Giuliani | M | 52 | 4 years | |
| David Hodgson | M | 67 | 2 years | |
| Jane Ryan | M | 65 | 4 years | |
| James Reddoch | M | 54 | 16 years | |
| Virginia DeJesus-Rueff | F | - | - | |
| David Wehner | M | 54 | 6 years | |
| Marshall Urist | M | 48 | 11 years | |
| David Wilson | M | 61 | 8 years | |
| Dimitri Grigoriadis | M | 65 | 31 years | |
| Henry Fernandez | M | 65 | 4 years | |
| Gregory Norden | M | 66 | 4 years | |
| Richard Scheller | M | 70 | 6 years | |
| Sean Weisberg | M | - | 4 years | |
| Arthur McGivern | M | - | 2 years | |
| Ted Love | M | 65 | 4 years | |
| Kristin Stafford | F | 43 | 8 years | |
| Richard Pops | M | 62 | 26 years | |
| Steven Hyman | M | 71 | 2 years | |
| Bill Wilson | M | - | 28 years | |
| Laurence Reilly | M | 42 | - | |
| Sarah Cata | F | - | 10 years | |
| Alessandra Sassun | F | - | 4 years | |
| Mina Fukuda | F | - | 9 years | |
| Sara Klymkowsky | F | - | 12 years | |
| Jessica Veeramachaneni | F | - | 13 years | |
| Dana Flanders | M | - | 3 years | |
| John F. Chin | M | 58 |
Aventis Pharmaceuticals, Inc.
 Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | 26 years |
| Gary Romano | M | 63 | 2 years | |
| Katie Hogan | F | - | - | |
| Clare Hunt | F | - | 7 years | |
| Kristina Cutter | F | - | 5 years | |
| Gabriel Alvarado | M | - |
nLife Therapeutics SL
nLife Therapeutics SL Pharmaceuticals: MajorHealth Technology nLife Therapeutics SL develops and manufactures pharmaceutical preparations. It specializes in oligonucleotides as therapeutic agents for central nervous system and neuromuscular disorders. The company was founded by Andres Pablo Montefeltro on September 24, 2009 and is headquartered in Armilla, Spain. | - |
| Brienne Kugler | F | - | 10 years | |
| Sandy Balkin | M | - | 3 years | |
| Terrance Coyne | M | 42 | 14 years | |
| Timothy Cunningham | M | 62 | 1 years | |
| Peter Heutink | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John P. Richard | M | 66 |
Targacept, Inc.
 Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 13 years |
| Solomon Steiner | M | 86 |
Biodel, Inc.
 Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | 8 years |
| Stephen Hill | M | 65 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 7 years |
| Alan Musso | M | 62 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 12 years |
| Joseph deBethizy | M | 74 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 15 years |
| Julia Brown | F | 76 |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT.
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | - |
| John Kelley | M | 70 |
Hoechst Marion Roussel, Inc.
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | 9 years |
| Joseph A. Mollica | M | 83 | 20 years | |
| Pierre Legault | M | 63 |
Hoechst Marion Roussel, Inc.
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | 5 years |
| Seline E. Miller | F | 55 | 2 years | |
| Stephen Birrell | M | - | 11 years | |
| Graeme Roy Kaufman | M | 74 | 4 years | |
| Andreas Busch | M | 59 |
Hoechst Marion Roussel, Inc.
| 6 years |
| John Duncan Higgons | M | 69 |
Archemix Corp.
 Archemix Corp. Miscellaneous Commercial ServicesCommercial Services Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA. | 3 years |
| Wylie W. Vale | M | 82 | - | |
| C. Payne | M | 61 | 4 years | |
| Augustine Lawlor | M | 67 | 8 years | |
| Gerard Michel | M | 60 |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | 7 years |
| Brian Pereira | M | 65 |
Biodel, Inc.
Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | 8 years |
| Alan Dunton | M | 70 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 10 years |
| G. Steven Burrill | M | 79 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 13 years |
| Mark B. Skaletsky | M | 75 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 12 years |
| Anjeza Gjino | F | 41 | 4 years | |
| Margaret E. Valeur-Jensen | M | 67 | - | |
| Chuck Wilson | M | 59 |
Archemix Corp.
Archemix Corp. Miscellaneous Commercial ServicesCommercial Services Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA. | 7 years |
| Lawrence Steinman | M | 76 | 8 years | |
| Trevor William Tappenden | M | - | 10 years | |
| Robert G. Schaub | M | - |
Archemix Corp.
Archemix Corp. Miscellaneous Commercial ServicesCommercial Services Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA. | - |
| Andrea Hunt | F | 64 | 6 years | |
| Kevin B. Churchwell | M | 62 | 2 years | |
| Scott Struthers | M | 62 | 10 years | |
| Andrew Hetherington | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 87 | 87.00% |
| Australia | 13 | 13.00% |
| Spain | 2 | 2.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Errol de Souza
- Personal Network
